Prof Salles provided an update on the ongoing first-line follicular lymphoma (FL) studies, demonstrating how analysis of the GALLIUM study data regarding…

Cesar Sanz Rodriguez is Associate Vice President, Medical Affairs Lead Mid-Europe (MER), Eastern Europe, Middle East & Africa (EEMEA) Regions. He spoke to us about his progression into medical affairs from a clinical background, the changing role of medical affairs in the pharma industry, and the exciting advances currently taking place in cancer treatment.

Karsten Lollike is the Corporate Vice President and the Qualified Person Responsible for Pharmacovigilance (QPPV) of Global Safety at Novo Nordisk, a position he has held for 11 years. Dr. Lollike joined Novo Nordisk in 2000, working in Global Development in Haemostasis, after obtaining his medical degree and subsequently a PhD. We spoke to Dr. Lollike about his medical expertise and experience, his long-standing career at Novo Nordisk, and what working at the company means to him.

NephMadness, now in its 7th year, is a derivative of the annual USA collegiate basketball championships, colloquially known as March Madness.

Affecting up to 11.4% of the population worldwide, psoriasis is one of the most common chronic autoinflammatory diseases.

This review starts with an excellent description of the pathophysiology of bronchopulmonary dysplasia, which should be informative to physicians who will…

Whoever you are, you have the power to reduce the impact of cancer for yourself, the people you love, and for the world. It’s time to make a personal…

Pol Vandenbroucke holds the position of Chief Medical Officer for Pfizer’s recently established Hospital Business Unit, a position he was promoted to at the start of 2019. We spoke to Vandenbroucke about how he applies his 30+ years of industry experience to his role today, and Medical Affairs’ evolving role in the development of medicines, ahead of his upcoming speech at eyeforpharma, Barcelona, 2019.

Ameet Nathwani is Chief Medical Officer and Executive Vice President at Sanofi. As a person well known for his interest and work in the use of new technologies in healthcare, he spoke to us about the changes these innovations are making to the pharmaceutical industry and the potential they have to transform the way patients are treated in the future.